FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211422285> ?p ?o ?g. }

• W3211422285 endingPage "2155" @default.
• W3211422285 startingPage "2140" @default.
• W3211422285 abstract "GSK3358699 is a mononuclear myeloid-targeted bromodomain and extra-terminal domain (BET) family inhibitor which demonstrates immunomodulatory effects in vitro. This phase 1, randomized, first-in-human study evaluated the safety, pharmacokinetics, and pharmacodynamics of GSK3358699 in healthy male participants (NCT03426995).Part A (N = 23) included three dose-escalating periods of 1-40 mg of GSK3358699 or placebo in two cohorts in a single ascending-dose crossover design. Part C (N = 25) was planned as an initial dose of 10 mg of GSK3358699 or placebo daily for 14 days followed by selected doses in four sequential cohorts.In part A, exposure to GSK3358699 and its metabolite GSK3206944 generally increased with increasing doses. The median initial half-life ranged from 0.7 to 1.1 (GSK3358699) and 2.1 to 2.9 (GSK3206944) hours after a single dose of 1-40 mg. GSK3206944 concentrations in monocytes were quantifiable at 1-hour post-dose following 10 mg of GSK3358699 and 1 and 4 hours post-dose following 20-40 mg. Mean predicted percentage inhibition of ex vivo lipopolysaccharide-induced monocyte chemoattractant protein (MCP)-1 reached 75% with 40 mg of GSK3358699. GSK3358699 did not inhibit interleukin (IL)-6 and tumour necrosis factor (TNF). The most common adverse event (AE) was headache. Four AEs of nonsustained ventricular tachycardia were observed across parts A and C. One serious AE of atrial fibrillation (part C) required hospitalization.Single doses of GSK3358699 are generally well tolerated with significant metabolite concentrations detected in target cells. A complete assessment of pharmacodynamics was limited by assay variability. A causal relationship could not be excluded for cardiac-related AEs, resulting in an inability to identify a suitable repeat-dose regimen and study termination." @default.
• W3211422285 created "2021-11-22" @default.
• W3211422285 creator A5005394094 @default.
• W3211422285 creator A5005514153 @default.
• W3211422285 creator A5011199254 @default.
• W3211422285 creator A5021869798 @default.
• W3211422285 creator A5029447427 @default.
• W3211422285 creator A5047834135 @default.
• W3211422285 creator A5060232437 @default.
• W3211422285 creator A5062897512 @default.
• W3211422285 creator A5066200967 @default.
• W3211422285 creator A5067085873 @default.
• W3211422285 creator A5069972259 @default.
• W3211422285 creator A5080704652 @default.
• W3211422285 creator A5083868830 @default.
• W3211422285 creator A5084163133 @default.
• W3211422285 creator A5087101589 @default.
• W3211422285 creator A5088143559 @default.
• W3211422285 creator A5088973852 @default.
• W3211422285 creator A5088991736 @default.
• W3211422285 creator A5089360528 @default.
• W3211422285 date "2021-12-18" @default.
• W3211422285 modified "2023-10-13" @default.
• W3211422285 title "A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid‐targeted bromodomain and extra‐terminal domain inhibitor" @default.
• W3211422285 cites W1120935590 @default.
• W3211422285 cites W1592012543 @default.
• W3211422285 cites W1635215145 @default.
• W3211422285 cites W1982085112 @default.
• W3211422285 cites W2055215337 @default.
• W3211422285 cites W2123383613 @default.
• W3211422285 cites W2150469988 @default.
• W3211422285 cites W2592276570 @default.
• W3211422285 cites W2924307212 @default.
• W3211422285 cites W2968167834 @default.
• W3211422285 cites W3020029031 @default.
• W3211422285 cites W3047620480 @default.
• W3211422285 cites W3087130502 @default.
• W3211422285 cites W3121466164 @default.
• W3211422285 cites W3121733667 @default.
• W3211422285 cites W3211422285 @default.
• W3211422285 doi "https://doi.org/10.1111/bcp.15137" @default.
• W3211422285 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34773923" @default.
• W3211422285 hasPublicationYear "2021" @default.
• W3211422285 type Work @default.
• W3211422285 sameAs 3211422285 @default.
• W3211422285 citedByCount "3" @default.
• W3211422285 countsByYear W32114222852021 @default.
• W3211422285 countsByYear W32114222852022 @default.
• W3211422285 crossrefType "journal-article" @default.
• W3211422285 hasAuthorship W3211422285A5005394094 @default.
• W3211422285 hasAuthorship W3211422285A5005514153 @default.
• W3211422285 hasAuthorship W3211422285A5011199254 @default.
• W3211422285 hasAuthorship W3211422285A5021869798 @default.
• W3211422285 hasAuthorship W3211422285A5029447427 @default.
• W3211422285 hasAuthorship W3211422285A5047834135 @default.
• W3211422285 hasAuthorship W3211422285A5060232437 @default.
• W3211422285 hasAuthorship W3211422285A5062897512 @default.
• W3211422285 hasAuthorship W3211422285A5066200967 @default.
• W3211422285 hasAuthorship W3211422285A5067085873 @default.
• W3211422285 hasAuthorship W3211422285A5069972259 @default.
• W3211422285 hasAuthorship W3211422285A5080704652 @default.
• W3211422285 hasAuthorship W3211422285A5083868830 @default.
• W3211422285 hasAuthorship W3211422285A5084163133 @default.
• W3211422285 hasAuthorship W3211422285A5087101589 @default.
• W3211422285 hasAuthorship W3211422285A5088143559 @default.
• W3211422285 hasAuthorship W3211422285A5088973852 @default.
• W3211422285 hasAuthorship W3211422285A5088991736 @default.
• W3211422285 hasAuthorship W3211422285A5089360528 @default.
• W3211422285 hasBestOaLocation W32114222851 @default.
• W3211422285 hasConcept C111113717 @default.
• W3211422285 hasConcept C112705442 @default.
• W3211422285 hasConcept C126322002 @default.
• W3211422285 hasConcept C137061746 @default.
• W3211422285 hasConcept C142724271 @default.
• W3211422285 hasConcept C150903083 @default.
• W3211422285 hasConcept C185592680 @default.
• W3211422285 hasConcept C197934379 @default.
• W3211422285 hasConcept C202751555 @default.
• W3211422285 hasConcept C204787440 @default.
• W3211422285 hasConcept C207001950 @default.
• W3211422285 hasConcept C27081682 @default.
• W3211422285 hasConcept C2781184567 @default.
• W3211422285 hasConcept C55493867 @default.
• W3211422285 hasConcept C71924100 @default.
• W3211422285 hasConcept C86803240 @default.
• W3211422285 hasConcept C87813604 @default.
• W3211422285 hasConcept C98274493 @default.
• W3211422285 hasConceptScore W3211422285C111113717 @default.
• W3211422285 hasConceptScore W3211422285C112705442 @default.
• W3211422285 hasConceptScore W3211422285C126322002 @default.
• W3211422285 hasConceptScore W3211422285C137061746 @default.
• W3211422285 hasConceptScore W3211422285C142724271 @default.
• W3211422285 hasConceptScore W3211422285C150903083 @default.
• W3211422285 hasConceptScore W3211422285C185592680 @default.
• W3211422285 hasConceptScore W3211422285C197934379 @default.
• W3211422285 hasConceptScore W3211422285C202751555 @default.
• W3211422285 hasConceptScore W3211422285C204787440 @default.
• W3211422285 hasConceptScore W3211422285C207001950 @default.

• next